{"id":660375,"date":"2019-02-21T13:30:00","date_gmt":"2019-02-21T13:30:00","guid":{"rendered":"https:\/\/www.pm360online.com\/?guid=c0e57911c724cef11564bd8049c726a1"},"modified":"2019-02-21T13:30:00","modified_gmt":"2019-02-21T13:30:00","slug":"amgen-cytokinetics-and-servier-announce-start-of-meteoric-hf-the-second-phase-3-clinical-trial-of-omecamtiv-mecarbil-in-patients-with-heart-failure-4","status":"publish","type":"post","link":"https:\/\/www.pm360online.com\/amgen-cytokinetics-and-servier-announce-start-of-meteoric-hf-the-second-phase-3-clinical-trial-of-omecamtiv-mecarbil-in-patients-with-heart-failure-4\/","title":{"rendered":"Amgen, Cytokinetics and Servier Announce Start of METEORIC-HF, the Second Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure"},"content":{"rendered":"<p><![CDATA[THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. and SURESNES,&#160;France, Feb.  21, 2019  (GLOBE NEWSWIRE) -- Amgen (NASDAQ: AMGN), Cytokinetics, Incorporated (NASDAQ: CYTK) and Servier today announced that METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecarbil Related to Increased Contractility in Heart Failure), the second Phase 3 clinical trial of omecamtiv mecarbil, a novel cardiac myosin activator, is open to enrollment. Omecamtiv mecarbil is being developed for the potential treatment of heart failure with reduced ejection fraction (HFrEF).]]><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":74553,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[71350,71351],"tags":[],"_links":{"self":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/posts\/660375"}],"collection":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/users\/74553"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/comments?post=660375"}],"version-history":[{"count":0,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/posts\/660375\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/media?parent=660375"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/categories?post=660375"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/tags?post=660375"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}